Litigation

Recent Posts

William A. Ruskin: Hand Over The Cash Or The Hard Drive Gets It!
Posted on 22 Nov 2013 by William A. Ruskin

By William A. Ruskin | In January 2013, GlaxoSmithKline (“GSK”) filed a complaint in New York state court alleging that its e-discovery vendor, Discovery Works Legal Inc., was “holding hostage over 20 terabytes of GSK’s most... Read More

Glaxo Takes $2.36 Billion Charge On Legal Costs
Posted on 15 Jul 2010 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) Pharmaceutical company GlaxoSmithKline said Thursday it expects to take a $2.36 billion charge against second-quarter earnings for the costs of settling court cases over the antidepressant Paxil and diabetes drug Avandia. The company said... Read More

Glaxo Settles Bad Drug Claim For More Than $40 Million
Posted on 24 Jun 2011 by LexisNexis Litigation Resource Community Staff

PROVIDENCE, R.I. - (AP) The American subsidiary of a major British drug maker, GlaxoSmithKline LLC, has agreed to pay more than $40 million to 37 states and Washington, D.C., to settle complaints alleging manufacturing process issues at a now-shuttered... Read More

Glaxo Partner Pronova Settles Lovaza Patent Lawsuit
Posted on 31 Mar 2011 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) GlaxoSmithKline PLC says U.S. patent litigation over the Omega-3 Lovaza drug has been settled, allowing generic drug company Apotex to eventually bring a competitor to market. Glaxo said Wednesday that Norway's Pronova BioPharma, which... Read More

Watchdog Group Makes 2nd Push To Ban Diet Pill
Posted on 15 Apr 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) For the second time in five years, public health advocates are calling on the Food and Drug Administration to ban a fat-blocking drug sold over-the counter and via prescription, pointing to new reports of kidney stones and pancreatic... Read More

Most FDA Advisers Recommend Avandia Stay On The Market
Posted on 14 Jul 2010 by Tom Moylan

GAITHERSBURG, Md. - (Mealey's) A majority of Food and Drug Administration advisers voted July 14 to keep Avandia on the market but split on whether the anti-diabetes drug made by GlaxoSmithKline PLC (GSK) should carry additional warnings about its... Read More

3rd Circuit: Humana Can Sue GSK For Reimbursement For Avandia-Related Expenses
Posted on 29 Jun 2012 by Tom Moylan

PHILADELPHIA - (Mealey's) Medicare Advantage provider Humana Medical Plan Inc. is allowed under Medicare law to seek reimbursement from GlaxoSmithKline PLC (GSK) for the costs of treating insurance customers who were injured by GSK's Avandia diabetes... Read More

$2.36B Glaxo Charge Covers Avandia, Paxil Litigation, Other Legal Costs
Posted on 15 Jul 2010 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and... Read More

2 Attorneys Settle Their Avandia Cases In Federal, State Courts
Posted on 10 May 2010 by Tom Moylan

PHILADELPHIA — (Mealey’s) Two attorneys have settled their Avandia personal injury cases in federal and state courts with defendant GlaxoSmithKline plc, a source told Mealey Publications May 10. According to the source, W. Mark Lanier of... Read More

A Word Change Here And There and Voila! GlaxoSmithKline Has Itself 33 New Avandia Experts
Posted on 17 Aug 2010 by Tom Moylan

So you saw the words "$2.36 billion," "settlement," and "Avandia" used in the same sentence and you think the litigation is over? Well, the old gal's still kicking and nowhere was that more apparent that in GSK's... Read More

Split U.S. Supreme Court Says Pharmaceutical Sales Reps Are Not Owed Overtime
Posted on 19 Jun 2012 by Bajeerah LaCava

WASHINGTON, D.C. - (Mealey's) A pharmaceutical sales representative, or detailer, falls under the U.S. Department of Labor's (DOL) definition of an "outside salesman" and is not owed overtime compensation, a split U.S. Supreme Court... Read More

GlaxoSmithKline To Settle 3 Federal Investigations For $3 Billion
Posted on 4 Nov 2011 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline plc (GSK) has reached an agreement in principal to settle three United States federal criminal and civil investigations for $3 billion, the company said Nov. 3 in a press release on its Web site. GSK said... Read More